 | • レポートコード：MRC2303F0016 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、237ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医薬品 |
| Single User（1名利用、印刷可） | ￥732,452 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,472,452 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本調査資料によると、2021年に289.1億ドルであった世界の獣医用医薬品市場規模が、2022年に329.5億ドルになり、予測期間中（〜2027年）にCAGR14.21%で成長し641.9億ドルまで達すると展望されています。本書は、獣医用医薬品の世界市場について総合的に分析し、市場規模・動向・予測などを整理しています。序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、製品別（獣医用抗生物質、獣医用寄生虫駆除剤、獣医用ワクチン）分析、ワクチン別（弱毒化ワクチン、不活性化ワクチン、組換えワクチン）分析、抗生物質別（アミノグリコシド、マクロライド、ペニシリン、スルホンアミド、テトラサイクリン）分析、エンドユーザー別（動物クリニック、動物病院）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報など、以下の構成で掲載しています。また、主要企業として、Biogenesis Bago、Boehringer Ingelheim GmbH、Ceva Santé Animale、Elanco、Hester Biosciences、Indian Immunologicals Ltd.、Kindred Biosciences, Inc.、Merck Animal Health、Neogen Corporation、Nutreco N.V.、Phibro Animal Health、Vetoquinol S.A.、Virbac、Zoetisなどの情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の獣医用医薬品市場規模：製品別 - 獣医用抗生物質の市場規模 - 獣医用寄生虫駆除剤の市場規模 - 獣医用ワクチンの市場規模 ・世界の獣医用医薬品市場規模：ワクチン別 - 弱毒化ワクチンの市場規模 - 不活性化ワクチンの市場規模 - 組換えワクチンの市場規模 ・世界の獣医用医薬品市場規模：抗生物質別 - アミノグリコシドの市場規模 - マクロライドの市場規模 - ペニシリンの市場規模 - スルホンアミドの市場規模 - テトラサイクリンの市場規模 ・世界の獣医用医薬品市場規模：エンドユーザー別 - 動物クリニックにおける市場規模 - 動物病院における市場規模 ・世界の獣医用医薬品市場規模：地域別 - 南北アメリカの獣医用医薬品市場規模 アメリカの獣医用医薬品市場規模 カナダの獣医用医薬品市場規模 ブラジルの獣医用医薬品市場規模 … - アジア太平洋の獣医用医薬品市場規模 日本の獣医用医薬品市場規模 中国の獣医用医薬品市場規模 インドの獣医用医薬品市場規模 韓国の獣医用医薬品市場規模 台湾の獣医用医薬品市場規模 … - ヨーロッパ/中東/アフリカの獣医用医薬品市場規模 イギリスの獣医用医薬品市場規模 ドイツの獣医用医薬品市場規模 フランスの獣医用医薬品市場規模 ロシアの獣医用医薬品市場規模 … - その他地域の獣医用医薬品市場規模 ・競争状況 ・企業情報 |
The Global Veterinary Pharmaceuticals Market size was estimated at USD 28.91 billion in 2021 and expected to reach USD 32.95 billion in 2022, and is projected to grow at a CAGR 14.21% to reach USD 64.19 billion by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Veterinary Pharmaceuticals to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Product, the market was studied across Veterinary Antibiotics, Veterinary Parasiticides, and Veterinary Vaccines.
Based on Vaccines, the market was studied across Attenuated Vaccines, Inactivated Vaccines, and Recombinant Vaccines.
Based on Antibiotics, the market was studied across Aminoglycosides, Macrolides, Penicillins, Sulphonamides, and Tetracyclines.
Based on End User, the market was studied across Veterinary Clinics and Veterinary Hospitals.
Based on Animal, the market was studied across Companion Animals and Livestock.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Veterinary Pharmaceuticals market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Veterinary Pharmaceuticals Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Veterinary Pharmaceuticals Market, including Biogenesis Bago, Boehringer Ingelheim GmbH, Ceva Santé Animale, Elanco, Hester Biosciences, Indian Immunologicals Ltd., Kindred Biosciences, Inc., Merck Animal Health, Neogen Corporation, Nutreco N.V., Phibro Animal Health, Vetoquinol S.A., Virbac, and Zoetis.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Veterinary Pharmaceuticals Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Veterinary Pharmaceuticals Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Veterinary Pharmaceuticals Market?
4. What is the competitive strategic window for opportunities in the Global Veterinary Pharmaceuticals Market?
5. What are the technology trends and regulatory frameworks in the Global Veterinary Pharmaceuticals Market?
6. What is the market share of the leading vendors in the Global Veterinary Pharmaceuticals Market?
7. What modes and strategic moves are considered suitable for entering the Global Veterinary Pharmaceuticals Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising consumption of meats and mandatory vaccination
5.1.1.2. Increasing animal ownership and care and growing penetration of pet insurance
5.1.1.3. Growing availability of targeted veterinary drugs for treatment of several diseases
5.1.2. Restraints
5.1.2.1. Lack of veterinary infrastructure facilities
5.1.3. Opportunities
5.1.3.1. Growth in R&D and procedural advancements to treat various diseases
5.1.3.2. Expansion of animal healthcare expenditure
5.1.4. Challenges
5.1.4.1. Use of counterfeit medicines
5.2. Cumulative Impact of COVID-19
6. Veterinary Pharmaceuticals Market, by Product
6.1. Introduction
6.2. Veterinary Antibiotics
6.3. Veterinary Parasiticides
6.4. Veterinary Vaccines
7. Veterinary Pharmaceuticals Market, by Vaccines
7.1. Introduction
7.2. Attenuated Vaccines
7.3. Inactivated Vaccines
7.4. Recombinant Vaccines
8. Veterinary Pharmaceuticals Market, by Antibiotics
8.1. Introduction
8.2. Aminoglycosides
8.3. Macrolides
8.4. Penicillins
8.5. Sulphonamides
8.6. Tetracyclines
9. Veterinary Pharmaceuticals Market, by End User
9.1. Introduction
9.2. Veterinary Clinics
9.3. Veterinary Hospitals
10. Veterinary Pharmaceuticals Market, by Animal
10.1. Introduction
10.2. Companion Animals
10.3. Livestock
11. Americas Veterinary Pharmaceuticals Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Veterinary Pharmaceuticals Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Veterinary Pharmaceuticals Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. FPNV Positioning Matrix
14.1.1. Quadrants
14.1.2. Business Strategy
14.1.3. Product Satisfaction
14.2. Market Ranking Analysis, By Key Player
14.3. Market Share Analysis, By Key Player
14.4. Competitive Scenario
14.4.1. Merger & Acquisition
14.4.2. Agreement, Collaboration, & Partnership
14.4.3. New Product Launch & Enhancement
14.4.4. Investment & Funding
14.4.5. Award, Recognition, & Expansion
15. Company Usability Profiles
15.1. Biogenesis Bago
15.1.1. Business Overview
15.1.2. Key Executives
15.1.3. Product & Services
15.2. Boehringer Ingelheim GmbH
15.2.1. Business Overview
15.2.2. Key Executives
15.2.3. Product & Services
15.3. Ceva Santé Animale
15.3.1. Business Overview
15.3.2. Key Executives
15.3.3. Product & Services
15.4. Elanco
15.4.1. Business Overview
15.4.2. Key Executives
15.4.3. Product & Services
15.5. Hester Biosciences
15.5.1. Business Overview
15.5.2. Key Executives
15.5.3. Product & Services
15.6. Indian Immunologicals Ltd.
15.6.1. Business Overview
15.6.2. Key Executives
15.6.3. Product & Services
15.7. Kindred Biosciences, Inc.
15.7.1. Business Overview
15.7.2. Key Executives
15.7.3. Product & Services
15.8. Merck Animal Health
15.8.1. Business Overview
15.8.2. Key Executives
15.8.3. Product & Services
15.9. Neogen Corporation
15.9.1. Business Overview
15.9.2. Key Executives
15.9.3. Product & Services
15.10. Nutreco N.V.
15.10.1. Business Overview
15.10.2. Key Executives
15.10.3. Product & Services
15.11. Phibro Animal Health
15.11.1. Business Overview
15.11.2. Key Executives
15.11.3. Product & Services
15.12. Vetoquinol S.A.
15.12.1. Business Overview
15.12.2. Key Executives
15.12.3. Product & Services
15.13. Virbac
15.13.1. Business Overview
15.13.2. Key Executives
15.13.3. Product & Services
15.14. Zoetis
15.14.1. Business Overview
15.14.2. Key Executives
15.14.3. Product & Services
16. Appendix
16.1. Discussion Guide
16.2. License & Pricing